gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · ADCTHealthcarePharmaceuticals

ADC Therapeutics SA (ADCT)

$1.71+10.00%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.56▼ 62.68% in range
Nov 3, 2025Low $0.96 · High $4.88Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

ADC Therapeutics SA closed at $1.71 on Nov 4, up 10.00%, 65.1% below its 52-week closing high. Volume of 2.5M shares was 1.64× its 20-day average (above normal).

Split-adjusted performance: +34.3% over one month, -55.8% over six months, -59.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $19.25M, up 2.2% from a year earlier, with a net margin of -86.1%.

Short interest was 6.3M shares at the Oct 15 settlement, down 8.1% from the prior report (6.4% of float, 2.9 days to cover).

Market cap$217.7M127.7M shares
Revenue · quarter$19.2M+2.2% YoY
Diluted EPS$-0.11—
P/E · TTM—P/S 2.7×
Net margin-86.1%Gross 87.8%
Dividend yieldNone
52-week range0.96 – 4.88−65.1% from high
Volume2.5M1.64× 20-day avg
Volatility · 60d101.5%Annualised
Short % of float6.4%2.9 days to cover
Net cash$102.5MCash $219.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.2%1M +34.3%3M +50.9%6M −55.8%YTD −51.7%1Y −59.2%3Y +142.5%5Y −93.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum20
Revenue growth44
Net margin43
Value (low P/E)—
Size49

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short6.3M−8.1% vs prior
Days to cover2.9Settled Oct 15
% of float6.4%
Short vol. 10d40.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ADCTADC Therapeutics SA$1.71+10.00%−55.8%+2.2%−86.1%—$217.7M
KROSKeros Therapeutics$10.97+1.29%−6.9%−100.0%——$217.5MCompare
EVMNEvommune$6.01+1.18%−74.8%———$218.1MCompare
ELDNEledon Pharmaceuticals$2.77+5.53%−27.2%———$224.7MCompare
SIGASIGA Technologies$3.16+1.45%−32.9%−49.5%30.4%—$226.7MCompare
NATRNature's Sunshine Products$12.92+7.04%−50.8%+1.9%3.0%12.6$227.3MCompare
VNDAVanda Pharmaceuticals$3.81+1.47%−48.9%+24.1%−32.3%—$230.1MCompare
UPBUpstream Bio$3.75+10.62%−59.2%−17.5%−5136.1%—$205.4MCompare
RNACCartesian Therapeutics$6.77+5.62%−18.8%−100.0%——$204.8MCompare

News about ADC Therapeutics SA

All news →

No recent articles focused on ADC Therapeutics SA. 1 articles mention it in passing.

Quick answers

What does ADC Therapeutics SA do?
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors.
What is ADCT's market cap?
$217.67M, based on the Nov 4 close of $1.71.
Does ADC Therapeutics SA pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ADCT is sold short?
6.3M shares, 6.4% of float, as of Oct 15, 2026.
What sector is ADCT in?
Healthcare, in the Pharmaceuticals industry.

About ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

HQ: Epalinges, V8193 employeesListed May 15, 2020adctherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology